RPS3AP17

Across TCGA pan-cancer cohorts, RPS3AP17 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RPS3AP17 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher RPS3AP17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPS3AP17 expression acts as an unfavorable survival marker.

MESO, THCA, and THYM are the cancer types where RPS3AP17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.150	0.580	<.001	108	view →
THCA	DFS	Tertile	II,III,IV	0.146	0.804	<.001	36	view →
THYM	DFS	Tertile	II,III,IV	0.145	0.749	.003	33	view →
SARC	DFS	Tertile	All	0.166	0.618	<.001	33	view →
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	24	view →
LIHC	DFS	Tertile	III,IV	0.094	0.424	.003	18	view →
STAD	DFS	Quartile	II,III,IV	0.528	0.656	.020	15	view →
LGG	DFS	Tertile	All	0.505	0.853	.003	9	view →
KIRP	OS	Tertile	All	0.274	0.716	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RPS3AP17–MESO (OS)

Open the MESO breakdown →